The FDA approved the first nalmefene hydrochloride auto-injector (Zurnai) for use as an emergency treatment for opioid overdose in adults and children 12 years of age and older, the agency announced ...

Naloxone Auto-Injector is specifically designed to be a medical countermeasure for military personnel or chemical incident responders against the potential threat of exposure to synthetic opioids on ...

The first nalmefene hydrochloride (HCl) auto-injector (Zurnai) brings a new tool to the fight against the opioid overdose epidemic but is not without controversy. As reported earlier this month, the ...

Anaphylaxis is a serious, potentially life-threatening allergic reaction that can affect several organ systems in the body and may threaten breathing and blood circulation. The most common causes of ...

Please provide your email address to receive an email when new articles are posted on . Psoriasis patients who self-administer bimekizumab experienced similar levels of comfort and success with both ...

The Aidaptus ® disposable auto-injector platform, designed by Owen Mumford, will be jointly offered to global biopharma companies to support their drug development programs with engineering and ...

Phillips-Medisize, in collaboration with its customer, Ascendis Pharma, was recently recognized with a third industry award for the Skytrofa Auto-Injector. The Red Dot Award recognizes the drug ...

The US Food and Drug Administration (FDA) has approved the first nalmefene hydrochloride auto-injector (Zurnai; Purdue Pharma LP) for the treatment of known or suspected opioid overdose in people aged ...